Ovarian Cancer: is a cancer that ignites in the female organs that produce eggs (ovaries). Ovarian cancer frequently goes undetected until it has spread within the pelvis and belly. At this late stage, ovarian cancer is more severe to treat and can be fatal.
Date: September 20, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Variation in gene expression among cell types, tissues, and organisms is commonly examined by reverse transcription...
Date: May 24, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 7:00pm (CEST) NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are c...
Date: March 31, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CET) Formalin-fixed paraffin-embedded (FFPE) tissues are the most widely used clinical sample types in histology and molecular...
Date: June 8, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Most deaths from ovarian and endometrial cancer are due to high-grade subtypes that metastasize before they are detectable by available...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
Background: Healthcare access (HCA) encompasses five important dimensions: Affordability, Availability, Accessibility, Accommodation and Acceptability. Published studies of cancer typically...
Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize the...
The identification of novel drug targets and the development of next generation therapeutic strategies remain elusive goals for cancer researchers. We believe that the aberrant molecular eve...
ABSTRACT DATE: July 14, 2020 TIME: 7:00 am PDT, 10:00 am EDT This is the second topic in the webinar series on ‘ Predictive Genomics for Population & Personalized Health ’. C...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
Estrogen metabolism is the ability to favorably excrete potentially toxic estrogens through urine and sweat. Impaired estrogen metabolism is associated with Endometriosis and Polycystic Ovar...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
The microbiome signatures in the context of gynecologic cancers (endometrial and ovarian) and the potential for their clinical use will be discussed. The use of microfluidic technologies to i...
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. P...
With over 265,000 new cases per year and over 50,000 deaths, breast and ovarian cancers represent a significant health burden in the USA. Prior work has demonstrated that CD4 helper T c...
DATE: April 26, 2018TIME: 8:00am PST, 11:00am EST Engineered T cells expressing a tumor antigen-specific receptor have revolutionized the field of cancer therap...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...
Date: September 20, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 6:00pm (CEST) Variation in gene expression among cell types, tissues, and organisms is commonly examined by reverse transcription...
Date: May 24, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 7:00pm (CEST) NGS tumor profiling has become the mainstay of modern cancer therapy. Several NCCN-guided and FDA-approved therapies are c...
Date: March 31, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CET) Formalin-fixed paraffin-embedded (FFPE) tissues are the most widely used clinical sample types in histology and molecular...
Date: June 8, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Most deaths from ovarian and endometrial cancer are due to high-grade subtypes that metastasize before they are detectable by available...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results i...
Background: Healthcare access (HCA) encompasses five important dimensions: Affordability, Availability, Accessibility, Accommodation and Acceptability. Published studies of cancer typically...
Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize the...
The identification of novel drug targets and the development of next generation therapeutic strategies remain elusive goals for cancer researchers. We believe that the aberrant molecular eve...
ABSTRACT DATE: July 14, 2020 TIME: 7:00 am PDT, 10:00 am EDT This is the second topic in the webinar series on ‘ Predictive Genomics for Population & Personalized Health ’. C...
Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key a...
Estrogen metabolism is the ability to favorably excrete potentially toxic estrogens through urine and sweat. Impaired estrogen metabolism is associated with Endometriosis and Polycystic Ovar...
A subset of women with ovarian cancer will present with an apparently isolated adnexal mass. Many of these women will have early stage ovarian cancer with a relatively good prognosis. Unfortu...
Personalized medicine driven by genomic-based treatments continues to increase in importance. Representatives from two distinct healthcare entities – a regional reference lab and commun...
The microbiome signatures in the context of gynecologic cancers (endometrial and ovarian) and the potential for their clinical use will be discussed. The use of microfluidic technologies to i...
Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids – DNA, RNA and their modifications – and a focus on proteins and protein function. P...
With over 265,000 new cases per year and over 50,000 deaths, breast and ovarian cancers represent a significant health burden in the USA. Prior work has demonstrated that CD4 helper T c...
DATE: April 26, 2018TIME: 8:00am PST, 11:00am EST Engineered T cells expressing a tumor antigen-specific receptor have revolutionized the field of cancer therap...
We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one...
DATE: November 15, 2017TIME: 10:00AM PTInteractions between tumor and immune cells in the tumor microenvironment (TME) play a key role in tumor progression and treatment response, with...
Immunotherapy: An unprecedented opportunity-Long-lasting/curative treatments-Lower side effects-Wide applicability-Natural mechanism of action-Locally produced T cell therapies&...
There has been a great deal of renewed attention in immuno-oncology over the last decade. Therapies for cancer are being developed, approved, and administered that can either initiate,...